J&J's 6% slide on an imperfect quarter is a gift to prospective buyers

J&J's pharmaceutical division is humming along, and the MedTech problems should be temporary.

Summary aggregated from CNBC's public RSS feed. The full reporting belongs to CNBC — please read it on their site.